Cel Dwarfbody-Therapeutics (DB-Tx) is a new company, established in 2016 as a spin off from a frontrunner research team in Gastro-Intestinal Cancers in the AMC Amsterdam. DB-Tx aims to transform current, ineffective treatment of these aggressive cancer types by co-administering highly effective and safe low molecular weight antibodies (“Dwarfbodies®”) to significantly increase therapeutic outcome. The superiority of the Dwarfbodies® compared to competing molecules and their anticancer effects have been published in various high ranked journals. Now PANTREAT primarily aims at broadening the initial target market for the Dwarfbodies® by creating additional proof-of-concept, reports on production, test Trial Centers and a sound business plan. Results will be compiled into a sound company portfolio, which will form the basis for further development of the Dwarfbodies® and obtaining investments and supportive grants and partnerships. Finally, this will lead to highly attractive licencing deals from 2020 onwards. Dziedzina nauki medical and health sciencesclinical medicineoncologypancreatic cancermedical and health sciencesbasic medicinetoxicology Program(-y) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Temat(-y) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Zaproszenie do składania wniosków H2020-SMEInst-2016-2017 Zobacz inne projekty w ramach tego zaproszenia Szczegółowe działanie H2020-SMEINST-1-2016-2017 System finansowania SME-1 - SME instrument phase 1 Koordynator DWARFBODY-THERAPEUTICS WERKMAATSCHAPPIJ BV Wkład UE netto € 50 000,00 Adres KWEEKDUINWEG 12 2051 EL OVERVEEN Niderlandy Zobacz na mapie MŚP Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant. Tak Region West-Nederland Noord-Holland Agglomeratie Haarlem Rodzaj działalności Private for-profit entities (excluding Higher or Secondary Education Establishments) Linki Kontakt z organizacją Opens in new window Uczestnictwo w unijnych programach w zakresie badań i innowacji Opens in new window sieć współpracy HORIZON Opens in new window Koszt całkowity € 71 429,00